Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 18;6(5):675-9.
doi: 10.3980/j.issn.2222-3959.2013.05.24. eCollection 2013.

Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy

Orhan Ates  1 , Habip Bilen, Sadullah Keles, H Hakan Alp, Mevlüt Sait Keleş, Kenan Yıldırım, Osman Ondaş, L Can Pınar, Mustafa Civelekler, Orhan Baykal
Affiliations

Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy

Orhan Ates et al. Int J Ophthalmol. .

Abstract

Aim: To determine the relationship between proliferative diabetic retinopathy (PDRP) and plasma coenzyme Q10(CoQ10) concentration.

Methods: Patients with type 2 diabetes and PDRP were determined to be the case group (n=50). The control group was consist of healthy individuals (n=50). Plasma CoQ10 and malondialdehyde (MDA) levels were measured in both groups.

Results: Ubiquinone-10 (Coenzyme Q10) levels in PDRP and control subjects are 3.81±1.19µmol/L and 1.91±0.62µmol/L, respectively. Plasma MDA levels in PDRP and control subjects were 8.16±2µmol/L and 3.44±2.08µmol/L, respectively. Ratio of Ubiquinol-10/ubiquinone-10 in PDRP and control subjects were 0.26±0.16 and 1.41±0.68, respectively.

Conclusion: The ratio of ubiquinol-10/ubiquinone-10 is found lower in patients with PDRP. High levels of plasma ubiquinol-10/ubiquinone-10 ratio indicate the protective effect on diabetic retinopathy.

Keywords: coenzyme Q10; diabetic; retinopathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Levels of ubiquinone-10 in patient and control groups.
Figure 2
Figure 2. Ubiquinol-10/Ubiquinone-10 ratio in patient and control groups.
Figure 3
Figure 3. Levels of MDA in patient and control groups.
See this image and copyright information in PMC

References

    1. Son SM. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. Diabetes Metab J. 2012;36(3):190–198. - PMC - PubMed
    1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239. - PubMed
    1. Crawford TN, Alfaro DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009;5(1):8–13. - PubMed
    1. Gündüz K, Bakri SJ. Management of proliferative diabetic retinopathy. Compr Ophthalmol Update. 2007;8(5):245–256. - PubMed
    1. Ishibashi T. Cell biology of intraocular vascular diseases. Nihon Ganka Gakkai Zasshi. 1999;103(12):923–947. - PubMed

LinkOut - more resources